Article Figures & Data
Tables
ANA Type No. Patients (%) Systemic sclerosis-specific ANA Anticentromere antibody 91 (51) Antitopoisomerase I 16 (9) Anti-Th/To RNP 14 (8) Anti-PM-Scl 6 (3) Anti-RNA pol I, II, III (one I, III only) 5 (3) Anti-U3 RNP 3 (2) Connective tissue disease-associated ANA Anti-U1 RNP 15 (8) Anti-Ro and/or anti-La 3 (2) Other Unidentified ANA 22 (12) Negative 7 (4) - Table 2.
Associations of antinuclear antibodies (ANA) with continuous variables. Differences for which 95% CI do not overlap zero, and are therefore significant (p < 0.05), are shown in bold type. For t tests and multiple regression analysis, the difference between the mean for patients with each ANA and the mean for all patients without that ANA is shown. For Mann-Whitney U tests, the difference between median values for patients with each ANA and for all patients without that ANA is given.
Criteria Difference Between ACA (n = 91) and not ACA (95% CI) Difference Between Anti-topo I (n = 16) and Not Anti-topo I (95% CI) Difference Between Anti-RNP (n = 15) and not Anti-RNP (95% CI) Difference Between Anti-Th/To (n = 14) and Not Anti-Th/To (95% CI) Age at diagnosis of lcSSc, yrs 4.6 (1.0 to 8.2) −2.5 (−8.9 to 3.9) −8.6 (−15.1 to −2.0) −4.6 (−11.0 to 1.8) Skin score* −2 (−3 to 0) 2 (0 to 5) 0 (−2 to 2) 0 (−3 to 1) Expected FVC, % 11.6 (6.7 to 16.4) −9.1 (−23 to 5.0) −9.9 (−19.2 to −0.6) 1.1 (−6.4 to 14.6) Expected DLCO, % −0.18 (−5.1 to 4.7) −6.4 (−18 to 5.6) 2.4 (−6.8 to 11.7) −2.1 (−11.4 to 7.2) Expected KCO*, % −6 (−12 to 0) 6 (−5 to 15) 8 (−3 to 19) −2 (−14 to 11) Creatinine clearance** −12.4 (−21.5 to −3.3) 12.7 (−3.0 to 28.3) −0.9 (−17.5 to 15.7) 0.8 (−16.0 to 17.6) - Table 3.
Associations of antinuclear antibodies (ANA) with categorical variables. All data are percentages. Percentages of patients within each class of ANA who have certain characteristics are given with the probability value from Fisher’s exact test that these are the same percentages in the patients without each particular ANA. Comparisons significant at the 0.05 level are in bold type.
Criteria ACA Not ACA p Anti-topo I Not Anti-topo I p Anti-RNP Not Anti-RNP p Anti-Th/To Not Anti-Th/To p Telangiectasia 63 42 < 0.01 56 53 0.8 7 57 < 0.01 64 52 0.4 Calcinosis 24 15 0.13 31 18 0.3 0 21 0.05 21 19 0.7 Arthritis 29 41 0.12 31 35 1.0 40 34 0.8 50 33 0.2 Esophageal involvement 52 41 0.14 50 46 0.8 13 49 0.01 43 46 1.0 Pulmonary fibrosis 7 17 0.04 38 9 < 0.01 7 12 1.0 21 11 0.2 FVC/DLCO > 1.4 61 45 0.05 56 53 0.8 42 54 0.6 54 53 1.0 Pulmonary artery pressure > 30 mm Hg 9 6 0.6 0 8 0.6 0 8 0.6 8 7 1.0 -
ACA: anticentromere antibodies; FVC: forced vital capacity; DLCO: diffusing lung capacity for carbon monoxide.
-
